Menu
/REGISTER
Montecito
Pac Premier
Giving Guide
Loading...
You are here:  Home  >  'Genentech'
Latest

FDA decides not to approve Amgen biosimilar, at least for now

By   /  Friday, June 1st, 2018  /  Central Coast Health Watch, Latest news, Technology  /  Comments Off on FDA decides not to approve Amgen biosimilar, at least for now

This article is only available to Business Times subscribers Subscribers: LOG IN or REGISTER for complete digital access. Not a Subscriber? SUBSCRIBE for full access to our weekly newspaper, online edition and Book of Lists. Check the STATUS of your Subscription Account.

Read More →
Latest

Amgen partnering to develop new drugs

By   /  Friday, July 21st, 2017  /  Central Coast Health Watch, East Ventura County, Latest news, Tri-County Public Companies  /  Comments Off on Amgen partnering to develop new drugs

This article is only available to Business Times subscribers Subscribers: LOG IN or REGISTER for complete digital access. Not a Subscriber? SUBSCRIBE for full access to our weekly newspaper, online edition and Book of Lists. Check the STATUS of your Subscription Account.

Read More →
Latest

Amgen’s Kyprolis found to increase cancer survival rate

By   /  Thursday, July 13th, 2017  /  Central Coast Health Watch, East Ventura County, Latest news, Technology, Tri-County Public Companies  /  Comments Off on Amgen’s Kyprolis found to increase cancer survival rate

A Phase 3 clinical study of Amgen’s multiple myeloma drug Kyprolis showed that it increased overall survival rate when paired with lenalidomide and dexamethasone versus just those two drugs alone. The drug reduced the risk of death by 21 percent, and patients lived 7.9 months longer when on a regimen that included Kyprolis than those Read More →

Read More →
Latest

Genentech sues Amgen over biosimilar drug info

By   /  Monday, February 20th, 2017  /  Central Coast Health Watch, Latest news, Technology  /  Comments Off on Genentech sues Amgen over biosimilar drug info

Roch AG subsidiary Genentech filed a lawsuit against Amgen claiming the Thousand Oaks-based company obstructed its investigation of whether the biosimilar Amgen is developing for Genentech’s cancer treatment Avastin violates the company’s patents, according to reports Feb. 20. Sales for Avastin, a treatment for lung, colon, ovarian and other types of cancer, reached $6.8 billion Read More →

Read More →
Latest

Amgen alumni start their own biotech companies

By   /  Friday, August 19th, 2016  /  Central Coast Health Watch, East Ventura County, Top Stories, Top Story, West Ventura County  /  Comments Off on Amgen alumni start their own biotech companies

This article is only available to Business Times subscribers Subscribers: LOG IN or REGISTER for complete digital access. Not a Subscriber? SUBSCRIBE for full access to our weekly newspaper, online edition and Book of Lists. Check the STATUS of your Subscription Account.

Read More →
Latest

Amgen settles lawsuit, says biosimilar works as well as Herceptin

By   /  Thursday, July 21st, 2016  /  Central Coast Health Watch, Latest news  /  Comments Off on Amgen settles lawsuit, says biosimilar works as well as Herceptin

Amgen settled a lawsuit and released positive news about a breast cancer biosimilar this week. The Thousand Oaks-based biotech giant said July 20 the company reached a settlement stemming from a class action lawsuit involving shareholders who sued the company over shares bought from the company between April 22, 2004 and May 10, 2007. Amgen Read More →

Read More →